Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

PURPOSE: To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status o...

詳細記述

保存先:
書誌詳細
主要な著者: Siegel, Abby B., Cohen, Emil I., Ocean, Allyson, Lehrer, Deborah, Goldenberg, Alec, Knox, Jennifer J., Chen, Helen, Clark-Garvey, Sean, Weinberg, Alan, Mandeli, John, Christos, Paul, Mazumdar, Madhu, Popa, Elizabeta, Brown, Robert S., Rafii, Shahin, Schwartz, Jonathan D.
フォーマット: Artigo
言語:Inglês
出版事項: 2008
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3635806/
https://ncbi.nlm.nih.gov/pubmed/18565886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.15.9947
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料